<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33727253</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Isolated homozygous R217X <i>OPTN</i> mutation causes knock-out of functional C-terminal optineurin domains and associated oligodendrogliopathy-dominant ALS-TDP.</ArticleTitle><Pagination><StartPage>1022</StartPage><EndPage>1024</EndPage><MedlinePgn>1022-1024</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-325803</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7204-5385</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbagallo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keogh</LastName><ForeName>Michael John</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Biosciences Institute, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chinnery</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, MRC Mitochondrial Biology Unit, Cambridge, Cambridgeshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, Oxfordshire, UK olaf.ansorge@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ANSORGE/OCT14/877-792</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L022656/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TALBOT/OCT16/889-792</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C409460">OPTN protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33727253</ArticleId><ArticleId IdType="pmc">PMC8372379</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-325803</ArticleId><ArticleId IdType="pii">jnnp-2020-325803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Blitterswijk M, van Es MA, Hennekam EAM, et al. . Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 2012;21:3776&#x2013;84. 10.1093/hmg/dds199</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds199</ArticleId><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al. . Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223&#x2013;6. 10.1038/nature08971</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Bieniek KF, Finch N, et al. . Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 2015;130:77&#x2013;92. 10.1007/s00401-015-1436-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId><ArticleId IdType="pmc">PMC4470809</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaki T, Ito H, Komure O, et al. . Multiple proteinopathies in familial ALS cases with optineurin mutations. J Neuropathol Exp Neurol 2018;77:128&#x2013;38. 10.1093/jnen/nlx109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx109</ArticleId><ArticleId IdType="pubmed">29272468</ArticleId></ArticleIdList></Reference><Reference><Citation>Keogh MJ, Wei W, Wilson I, et al. . Genetic compendium of 1511 human brains available through the UK medical Research Council brain banks network resource. Genome Res 2017;27:165&#x2013;73. 10.1101/gr.210609.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.210609.116</ArticleId><ArticleId IdType="pmc">PMC5204341</ArticleId><ArticleId IdType="pubmed">28003435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al. . Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015;347:1436&#x2013;41. 10.1126/science.aaa3650</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortob&#xe1;gyi T, Troakes C, Nishimura AL, et al. . Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol 2011;121:519&#x2013;27. 10.1007/s00401-011-0813-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0813-3</ArticleId><ArticleId IdType="pubmed">21360076</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>